Treatment of Steroid-Refractory Immune Checkpoint-Related Hepatitis With Ruxolitinib

The incidence of immune-related hepatitis (IRH) is rising due to increasing use of immune checkpoint inhibitors for the treatment of several malignancies. While most cases respond to corticosteroid therapy, some patients require additional immunosuppressive agents, for which evidence to guide management is still evolving. We present the first documented case of ruxolitinib use as a tertiary agent for IRH following failure of corticosteroids and tocilizumab, suggesting a potential role for Janus kinase inhibitors as a rescue therapy for severe IRH.